SEC Form 4 · accession 0001209191-18-060006
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard Levy
Officer — Chief Medical Officer
Period of report
Nov 26, 2018
Accepted (ET)
Nov 27, 2018 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 26, 2018 | M | 149 | $4.63 | A | 7,709 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.63 | Nov 26, 2018 | M | 149 | D | — | Jul 11, 2027 | Common Stock | 149 | 87,118 | D |
Explanation of responses
- F1The Option vests monthly over a period of four years commencing June 15, 2017.